Search

everythinglearnresearchcommunity

for

Search:↓

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Early high-dose steroid treatment helps prolong disease-free periods in severe alopecia areata.

Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.

The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.

JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.

Budesonide alone is less effective than standard treatment for autoimmune hepatitis.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.

Pulsed electric field treatment may help shrink untreated liver tumors.

IL-1 alpha stops hair follicle growth and hair production.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

Upadacitinib improved multiple immune-related conditions in one patient.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

A new treatment called SAMiRNA-AR68 increases hair count in people with hair loss, showing similar results to existing treatments but without side effects.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.